Central Nervous System (CNS) drugs market consists of drugs used for the treatment of diseases have an effect on the brain such as epilepsy, Parkinson’s disease, depression and anxiety. Epilepsy is a chronic brain disorder characterized by frequent abductions. Parkinson’s disease is a degenerative CNS disorder associated with symptoms of rigidity and tremor. According to Parkinson’s disease Foundation nearly 7-10 Million people are affected with Parkinson’s disease across the globe. These diseases affect by the neurodegeneration, autoimmune disorders and trauma.
Increase in CNS diseases prevalence rates due to aging population, introduction of new class of drugs and increased expenditure on healthcare are the driving force for the growth of CNS Drugs market. In recent years, there is no drug available to cure Alzheimer’s disease, the available medicines only treat the austerity of symptoms and develop the quality of life to some extent. There are lots of companies such as Eli Lilly, Baxter International and Novartis AG are investing vigorously in research and development in order to accelerate the treatment of Alzheimer’s disease. Geographically, North America grabs the major share of the total market of CNS disorders. Europe and Asia Pacific holds the second and third highest market share. Asia Pacific is the boon for the lots of companies because of high prevalence of diseases such as epilepsy, Parkinson disease and Alzheimer’s disease.
Some of the key players operating in the market for CNS disorders are Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis AG, Sanofi, Merck & Co., Abbott Laboratories, Eli Lilly, UCB, Bristol-Meyers Squibb Co. and Astellas Pharma, Inc.
Alzheimer’s disease – A boon for the Pharmaceuticals Industry
Alzheimer’s disease drug market is on the decline stage. Since 2003, there is not any single drug launched in the market to prevent or cure it. However, all the current available drugs are going to be generic in 1-2 years. There are high unmet medical needs. The pharmaceuticals companies are looking for the opportunity which has lots of potential in the Alzheimer’s disease market. If the Pharmaceuticals companies have succeeded, they will be in a position to command premium prices and tap the existing opportunity.
From the year 2009 Alzheimer’s disease drug market is declining and it is expected to fall till 2016. But with the expected launch of some Alzheimer’s drugs from the year 2017 onwards, Alzheimer’s disease drug market is expected to revive in the coming years. However due to absence of exact potential drugs there will always remain a huge Unmet Alzheimer’s Drug Market. Alzheimer’s disease drug market declined year on year from the year 2009. It is expected to fall till 2016. Alzheimer’s disease drug market is expected to revive from the year 2017 onwards. There will always remain a huge Unmet Alzheimer’s Drug Market.